This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kwon, M. Articles by Libutti, S. K. Search for Related Content PubMed PubMed Citation Articles by Kwon, M. Articles by Libutti, S. K.

Functional Characterization of Filamin A Interacting Protein 1–Like, a Novel Candidate for Antivascular Cancer Therapy

¹ Tumor Angiogenesis Section, Surgery Branch and ² Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research and ³ Angiogenesis Core Facility, National Cancer Institute, NIH, Bethesda, Maryland; and ⁴ Protein Expression Laboratory, Advanced Technology Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, NIH, Frederick, Maryland

Requests for reprints: Steven K. Libutti, Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, Room 4W-5940, Building 10, 10 Center Drive, Bethesda, MD 20892. Phone: 301-496-5049; Fax: 301-402-1788; E-mail: libuttis{at}mail.nih.gov.

Key Words: angiogenesis • angiogenesis inhibitors • filip1l • antivascular reagent • cancer therapy

Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy. [Cancer Res 2008;68(18):7332–41]